AACR23 – New is not necessarily better
Orlando – At AACR23 the old adage of “be the first, or be the best” is well and truly on display when it comes to oncology drug development.
This should give heart to companies who break new ground.
Me-too drugs and follow-on innovation, however, has to deliver in terms of enhanced clinical benefit or a much improved toxicity profile.
At AACR23 we’ve already seen a few companies fall a bit short.
New does not always mean better – instead it may well be a case of ‘who dares wins’, to use the motto of the British SAS.
In this latest post we’re continuing our commentary and analysis of data presented at AACR23.
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
